ClinicalTrials.gg
CompletedNCT05123976Updated Nov 17, 2021

Fasted Bioequivalence Study of 2 Olanzapine Film-coated Tablets, 5 mg, in Healthy, Adult Male and Female Subjects.

A Phase 1 interventional study of Olanzapine film-coated tablets 5 mg (JSC Farmak, Ukraine) and Zyprexa® coated tablets 5 mg (Eli Lilly, Nederland B V) in Pharmacokinetics, sponsored by Joint Stock Company "Farmak". Completed at 1 site in Czechia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-17.

Sponsored by Joint Stock Company "Farmak" · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Oct 2020, registered Nov 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study was designed to assess the bioequivalence of Olanzapine tablets of two different manufacturers and to investigate the safety and tolerability of Olanzapine tablets of two different manufacturers.

Read the detailed description

A comparative, open-label, randomized, two-period, two-treatment, two-sequence, two-way crossover clinical trial to evaluate the bioequivalence of single doses of test product Olanzapine film-coated tablets 5 mg (JSC Farmak, Ukraine) and reference product Zyprexa® coated tablets 5 mg (Eli Lilly, Nederland B V) in healthy, adult male and female subjects under fasted conditions.

During each period 22 blood samples were taken in each Study Period: prior to dosing (-1.0) and 1.0, 2.0, 3.0, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 10.0, 12.0, 14.0, 16.0, 24.0, 48.0 and 72.0 hours after IMP administration.

02

Conditions studied

  • Pharmacokinetics

Keywords

  • bioequivalence
  • pharmacokinetics
  • generic drugs
  • Olanzapine
03

In context

Lead sponsor

Joint Stock Company "Farmak" is the lead sponsor of 12 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males and non-pregnant and no breast-feeding females ), ≥18 and ≤55 years of age ) (on the day of ). Caucasian race.
  2. Non-smoker or past-smoker (who has stopped smoking at least 6 months before the first dosing).
  3. (BMI) 18.5 to 30.0 kg/m2, inclusive and body weight between 50 kg and 100 kg (on the day of screening).
  4. Subject was available for the whole study and has provided his/her written informed consent.
  5. Subjects in good health, as determined by screening medical history, physical examination, vital signs assessments (pulse rate, systolic and diastolic blood pressure, and body temperature) and 12-lead . Minor deviations outside the reference ranges were acceptable, if deemed not by the Investigator.
  6. All laboratory screening results within the normal range. Minor deviations outside the reference ranges were acceptable, if deemed not clinically significant by the Clinical Investigator.
  7. Acceptance of use of measures during the whole study by both female and male subjects ).

Exclusion criteria

Exclusion Criteria:

  1. Gastrontestinal, renal or hepatic diseases and/or pathological findings present or in history, which might interfere with the drug pharmacokinetics. Any pre-existing disease or condition (e.g. hemicolectomy) for which it can be assumed that absorption, distribution, metabolism and excretion of the IMP will be affected.
  2. An unusual diet, for whatever reason (e.g. low-sodium), for four weeks prior to receiving the study drug. In any such case subject selection was at the discretion of the Principal Investigator.
  3. History, presence or known risk of narrow-angle glaucoma.
  4. Acute or chronic diseases and/or clinical finding which may interfere with the aims of the study or with the drug's safety, tolerability, bioavailability and/or pharmacokinetics of the IMP.
  5. Previous liver disease or elevations in serum transaminases or AST ≥ 1.0 at the screening.
  6. History of kidney disease and with impaired renal function.
  7. Known or idiosyncratic reaction to olanzapine or to any of its or any drug or any substance.
  8. Hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption.
  9. Any history or presence of asthma (including aspirin-induced asthma) or nasal polyp or NSAII induced urticaria.
  10. Presence of out-of-range cardiac interval on the at screening or other abnormalities, unless deemed non-significant by the Investigator.
  11. Clinically significant illness within 28 days before the first dosing, including major surgery.
  12. Any significant clinical abnormality, including a positive result of and/or and/or test during screening procedure.
  13. Positive result of blood pregnancy test at screening or positive urine pregnancy test at check-in or breast-feeding or lack of results of pregnancy test.
  14. Positive results of drugs in urine at screening and at check-in.
  15. Positive result of alcohol breath test at screening and at check-in.
  16. Positive result of urine cotinine test at screening.
  17. Serious mental disease and/or inability to cooperate with clinical team.
  18. Sitting blood pressure after a minimum of 5 minutes of rest is out of the range of 90-140 mmHg for systolic BP and/or 60-90 mmHg for diastolic BP and/or heart rate out of the range of 50-100 bpm during the screening procedure.
  19. Body ear temperature is out of the range of 35.7-37.6° C at screening and at check-in.
  20. Orthostatic hypotension during the screening procedure.
  21. Drug, alcohol (of ≥ 40 g per day pure ethanol), solvents or caffeine abuse.
  22. Use of organ-toxic drugs or systemic drugs known to substantially alter liver metabolism within 90 days before the first dosing.
  23. Use of any prescription medication for a period of 28 days before the first dosing.
  24. Use of any OTC (over-the-counter) medication including vitamins, herbal medications and food supplements less than 14 days before the first dosing.
  25. Getting a tattoo, body piercing or any cosmetic treatment involving skin piercing within 90 days before the screening unless evaluated by Investigator as non-significant for inclusion in the study.
  26. Donation or loss of at least 500 mL of blood within 90 days or donation of plasma or within 14 days before the first dosing.
  27. Subjects who have any clinically significant abnormal laboratory safety findings (upon repeat testing, 1 repeat assessment is acceptable) previously or at screening.

    1. Anaemia ( below 120 g/L for women and 130 g/L for men)
    2. Leukopenia (value of WBC below 4.00*10_9/L) and/or neutrophilopenia (value of NEU below 2.0 *10 9/L
    3. Thrombocytopenia (value of platelets below 150*10_9/L).
  28. Less thay 30 days between exit procedure in previous study and the first dosing in this study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Treatment A

    Olanzapine film-coated tablets 5 mg (JSC Farmak, Ukraine)

    Drug: Olanzapine film-coated tablets 5 mg (JSC Farmak, Ukraine)

  • Active comparator
    Treatment B

    Zyprexa® coated tablets 5 mg (Eli Lilly, Nederland B V)

    Drug: Zyprexa® coated tablets 5 mg (Eli Lilly, Nederland B V)

Interventions

06

What researchers measure

Primary outcomes

  1. AUC(0-72h)

    The area under the plasma concentration-time curve from time zero to sampling time 72 hours calculated by linear trapezoidal rule

    Time frame: up to 72 hours post-administration

  2. Cmax

    Maximum plasma concentration observed.

    Time frame: up to 72 hours post-administration

Secondary outcomes

  1. tmax.

    The time of the maximum plasma drug concentration

    Time frame: up to 72 hours post-administration

07

Study locations

1 site
  • QUINTA-ANALYTICA s.r.o.
    Prague, 10200, Czechia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Nov 2020, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2021
First posted
Nov 17, 2021
StartActual
Oct 21, 2020
Primary completionActual
Nov 30, 2020
CompletionActual
Nov 30, 2020
Last update
Nov 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05123976
Lead sponsor
Joint Stock Company "Farmak"
Responsible party
Sponsor
First posted
Nov 17, 2021
Start date
Oct 21, 2020
Primary completion
Nov 30, 2020
Completion
Nov 30, 2020
Last update
Nov 17, 2021

Study contacts

Vlad Udovytskyi
study chair · Joint Stock Company "Farmak"

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olanzapine

Start the discussion